By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TRACON Pharmaceuticals, Inc. 

4510 Executive Drive
Suite 330
San Diego  California  92121  U.S.A.
Phone: 858-550-0780 Fax: 858-550-0786



Company News
TRACON Pharma (TCON) Announces $21 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC 3/15/2017 10:42:14 AM
TRACON Pharma (TCON) Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update 3/1/2017 12:10:13 PM
TRACON Pharma (TCON) Announces First Patient Dosed In Phase III TAPPAS Trial Of TRC105 In Angiosarcoma 2/16/2017 8:22:35 AM
TRACON Pharma (TCON) Announces Top-Line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma 2/10/2017 8:49:11 AM
TRACON Pharma (TCON) Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase III Clinical Trial Of TRC105 In Angiosarcoma 1/3/2017 8:03:26 AM
TRACON Pharma (TCON) Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares 11/30/2016 8:13:32 AM
TRACON Pharma (TCON) Announces Pricing Of Public Offering Of Common Stock 11/23/2016 7:12:35 AM
TRACON Pharma (TCON) Announces Presentation Of Updated Data From Phase Ib/II Study Of TRC105 And Votrient In Patients With Angiosarcoma 11/11/2016 9:09:01 AM
TRACON Pharma (TCON) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/9/2016 8:35:29 AM
TRACON Pharma (TCON) To Report Third Quarter 2016 Company Highlights And Financial Results On November 8, 2016 11/2/2016 8:41:09 AM